Table III.
IC50 values of salinomycin and nanoparticles in prostate cancer cells at 72 h.
| IC50, µg/ml | ||||
|---|---|---|---|---|
| Treatment | CD44+ DU145 | CD44− DU145 | CD44+ 22RV1 | CD44− 22RV1 |
| Salinomycin | 5.3±2.3 | 15.9±7.6 | 7.7±5.3 | 17.7±5.4 |
| SM-LPN | 8.6±4.9 | 18.1±7.3 | 10.9±5.7 | 23.4±6.5 |
| SM-LPN-CD44 | 1.4±1.3 | 19.3±6.8 | 2.4±1.6 | 20.8±6.9 |
| LPN-CD44 | >300.0 | >300.0 | >300.0 | >300.0 |
Data are presented as mean ± standard deviation (n=3). SM-LPN, salinomycin-encapsulated lipid-poly(lactide-co-glycolide acid) nanoparticles; SM-LPN-CD44, salinomycin-encapsulated lipid-poly(lactide-co-glycolide acid) nanoparticles linked with CD44 antibodies; LPN-CD44, blank lipid-poly(lactide-co-glycolide acid) nanoparticles linked with CD44 antibodies; CD, cluster of differentiation; IC50, half maximal inhibitory concentration.